Cyclerion 10k
WebJan 26, 2024 · Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. ... risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in our 2024 Form 10-K filed on February 25, 2024, and our subsequent SEC filings including … WebJun 4, 2024 · Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, ... risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in our …
Cyclerion 10k
Did you know?
WebApr 3, 2024 · Cyclerion has entered an exclusive negotiation arrangement for a limited period to allow the parties to negotiate binding documentation. In addition, Cyclerion has entered into a binding agreement ... WebWe are led by an accomplished team with an exceptional track record of discovering, developing, and commercializing meaningful therapies for patients while creating value …
WebFeb 23, 2024 · Applicable risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in Cyclerion’s 2024 Form 10-K filed on February 25, 2024, and subsequent SEC ... WebDec 21, 2024 · Cyclerion’s lead program is CY6463, previously known as IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and...
WebAll Form Types. All Years. Date Filing Description Download. 04/04/2024. 3. Initial Statement of Beneficial Ownership. 04/03/2024. 4. Statement of Changes in Beneficial Ownership. WebApr 3, 2024 · Cyclerion’s portfolio includes novel sGC stimulators that modulate a key node in a fundamental signaling network in both the CNS and the periphery. The …
WebMar 22, 2024 · 10-K: CYCLERION THERAPEUTICS, INC. Published: March 22, 2024 at 4:58 p.m. ET ... Discussion and Analysis of Financial Condition and Results of Operations included in this Annual Report on Form 10 ...
WebMay 27, 2024 · Cyclerion is also advancing CY3018, a next-generation sGC stimulator. ... risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in our 2024 Form 10-K ... cleanzorb wipesWebJun 3, 2024 · Applicable risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in Cyclerion’s 2024 Form 10-K filed on February 25, 2024, and Cyclerion’s subsequent SEC filings, including the Form 10-Q filed on April 30, 2024. Investors are cautioned not to place undue reliance on these forward-looking statements. clean 下载WebJul 8, 2024 · Applicable risks and uncertainties include the risks listed under the heading “Risk Factors” and elsewhere in Cyclerion’s 2024 Form 10-K filed on February 25, 2024, and subsequent SEC filings including the Form 10-Q filed on April 30, 2024. Investors are cautioned not to place undue reliance on these forward-looking statements. These ... clean 鈥 soil air waterWebMar 27, 2024 · Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion’s portfolio includes novel sGC stimulators that modulate... cleanzo phenylWebApr 3, 2024 · Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases. Cyclerion’s portfolio includes novel sGC stimulators that modulate... clean 意味clean 意味はWebFeb 26, 2024 · – Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases – – Spin-off expected to be completed in early April 2024 – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Cyclerion Therapeutics, Inc. (Cyclerion) has entered into … clean 意味 名詞